ALAMEDA, Calif., Dec. 19, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.
Event: 41st Annual J.P. Morgan Healthcare Conference
Date: Monday, January 9, 2023
Time: 1:30pm ET/ 10:30am PT
A webcast of the presentation will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
investors@penumbrainc.com
| Last Trade: | US$296.05 |
| Daily Change: | -1.50 -0.50 |
| Daily Volume: | 542,037 |
| Market Cap: | US$11.360B |
April 23, 2025 February 18, 2025 December 30, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
